Get the Stockscreener App
27.51
0.43%
-0.12
After Hours:
27.51
Uniqure N V stock is traded at $27.51, with a volume of 612.86K.
It is down -0.43% in the last 24 hours and down -60.70% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$27.63
Open:
$27.73
24h Volume:
612.86K
Relative Volume:
0.14
Market Cap:
$1.71B
Revenue:
$14.34M
Net Income/Loss:
$-199.00M
P/E Ratio:
-7.0179
EPS:
-3.92
Net Cash Flow:
$-183.51M
1W Performance:
-1.08%
1M Performance:
-60.70%
6M Performance:
+82.91%
1Y Performance:
+356.98%
1-Day Range:
$26.77
$27.90
1-Week Range:
$26.76
$29.99
52-Week Range:
$5.89
$71.50
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
27.51 | 1.72B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
How sustainable is uniQure N.V. stock dividend payoutJuly 2025 Opening Moves & Stepwise Trade Signal Guides - moha.gov.vn
Market Pulse: Can uniQure N.V. stock surprise with earnings upsideWeekly Investment Report & Technical Entry and Exit Tips - moha.gov.vn
How uniQure N.V. stock benefits from tech adoptionJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - moha.gov.vn
uniQure put volume heavy and directionally bearish - TipRanks
uniQure (QURE) Is Down 5.9% After FDA Calls AMT-130 Data Insufficient for BLA Approval – Has the Bull Case Changed? - simplywall.st
uniQure is Now Oversold (QURE) - Nasdaq
William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty - MSN
Certain Performance Stock of uniQure N.V. are subject to a Lock-Up Agreement Ending on 25-NOV-2025. - MarketScreener
Certain Options of uniQure N.V. are subject to a Lock-Up Agreement Ending on 25-NOV-2025. - MarketScreener
Certain Ordinary Shares of uniQure N.V. are subject to a Lock-Up Agreement Ending on 25-NOV-2025. - MarketScreener
QURE Investigation Alert: Kessler Topaz Meltzer & Check, - GlobeNewswire
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
A significant driver of top-line growth: uniQure N.V (QURE) - Setenews
9 Oversold Biotech Stocks to Invest In - Insider Monkey
uniQure NV Faces Weak Start with 5.08% Gap Down Amid Market Concerns - Markets Mojo
QURE Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Eastern Progress
uniQure (NASDAQ:QURE) Downgraded by Wall Street Zen to “Sell” - Defense World
(QURE) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
Why uniQure N.V. (UQ1) stock is trending on social mediaJuly 2025 Breakouts & AI Optimized Trade Strategies - newser.com
How currency fluctuations impact uniQure N.V. stock - newser.com
Is uniQure N.V. stock a buy on dipsTrade Analysis Report & Daily Volume Surge Signals - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V.QURE - PR Newswire
Will uniQure N.V. stock deliver shareholder valueJuly 2025 Price Swings & Reliable Breakout Forecasts - newser.com
Is uniQure N.V. (UQ1) stock supported by strong fundamentals - newser.com
Reviewing uniQure (NASDAQ:QURE) and Biogen (NASDAQ:BIIB) - Defense World
Published on: 2025-11-19 17:01:52 - newser.com
Can uniQure N.V. stock hit record highs againTrade Volume Summary & Risk Controlled Stock Pick Alerts - newser.com
Predicting uniQure N.V. trend using moving averagesJuly 2025 PreEarnings & Reliable Intraday Trade Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against uniQure N.V. (QURE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - FinancialContent
Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA - MSN
Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3 - Insider Monkey
Can uniQure N.V. (UQ1) stock sustain revenue momentumQuarterly Earnings Summary & Detailed Earnings Play Strategies - newser.com
Can uniQure N.V. stock hit analyst price targetsTrade Risk Report & Safe Entry Point Identification - newser.com
Volatility clustering patterns for uniQure N.V.Gold Moves & Real-Time Chart Breakout Alerts - newser.com
Is uniQure N.V. stock a bargain at current levelsPortfolio Performance Report & Daily Volume Surge Signals - newser.com
uniQure N.V. Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure NV Faces Weak Start with 10.32% Gap Down Amid Market Concerns - Markets Mojo
Do Rising Losses at uniQure (QURE) Reflect Strategic Investment or Escalating Cost Pressure? - simplywall.st
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):